Search
CXD101
go.drugbank.com/drugs/DB16182InvestigationalCXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
Synonyms: Hdac-in-4Lorigerlimab
go.drugbank.com/drugs/DB18942InvestigationalLorigerlimab is under investigation in clinical trial NCT05848011 (A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-resistant Prostate Cancer).
(+)-Mefloquine
go.drugbank.com/drugs/DB05636Investigationalcompare the efficacy of (+) Mefloquine vs. racemic [Mefloquine]. … (+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to
Tecadenoson
go.drugbank.com/drugs/DB04954InvestigationalTecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.
Plamotamab
go.drugbank.com/drugs/DB18944InvestigationalPlamotamab is under investigation in clinical trial NCT05328102 (Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (
R112
go.drugbank.com/drugs/DB06252ExperimentalR112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.
ATL-104
go.drugbank.com/drugs/DB05670InvestigationalATL-104 is a potent mitogen for epithelial cells of the gastrointestinal tract. In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents.
Navocaftor
go.drugbank.com/drugs/DB19039InvestigationalNavocaftor is under investigation in clinical trial NCT04853368 (Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/navocaftor/abbv-119 or Galicaftor/navocaftor … /abbv-576 Combination Therapies in Adult Participants With Cystic Fibrosis).
Peptide YY (3-36)
go.drugbank.com/drugs/DB05004InvestigationalPeptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.
Deramciclane
go.drugbank.com/drugs/DB06512InvestigationalDeramciclane (EGIS-3886) is used for the treatment of a number of anxiety disorders. … Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target.